Protocol detail

Metastatic GIST: Imatinib and Sunitinib Failure

Protocol full text hidden due to copyright restrictions

However, the full text is available at the following link: Access Free Full Text.

Demetri G.D., Reichardt P., Kang Y.K., Blay J.Y., Rutkowski P., Gelderblom H., Hohenberger P., Leahy M., von Mehren M., Joensuu H., Badalamenti G., Blackstein M., Cesne A.L., Schöffski P., Maki R.G., Bauer S., Nguyen B.B., Xu J., Nishida T., Chung J., Kappeler C., Kuss I., Laurent D, & Casali P. (2012). Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: an international, multicentre, prospective, randomised, placebo-controlled phase 3 trial (GRID). Lancet, 381(9863), 10.1016/S0140-6736(12)61857-1.

Publication 2012

Cardiac Computed tomography Eligibility Gist Heterogeneity Imatinib Inhibitors Oncology Patients Progression Renal Sunitinib Therapy Vegfr

Corresponding Organization : Harvard University

Other organizations : Helios Hospital Bad Saarow, University of Ulsan, Asan Medical Center, Ulsan College, Centre Léon Bérard, Université Claude Bernard Lyon 1, The Maria Sklodowska-Curie National Research Institute of Oncology, Leiden University Medical Center, University of Mannheim, Heidelberg University, University Hospital Heidelberg, The Christie NHS Foundation Trust, Fox Chase Cancer Center, Helsinki University Hospital, University of Palermo, Mount Sinai Hospital, Institut Gustave Roussy, KU Leuven, Icahn School of Medicine at Mount Sinai, University of Duisburg-Essen, Institut Bergonié, Academy of Military Medical Sciences, Osaka Police Hospital, Bayer (United States), Bayer (Germany), Fondazione IRCCS Istituto Nazionale dei Tumori

Top 5 similar protocols

Protocol cited in 14 other protocols

Variable analysis

Dependent Variables detection not available due to copyright restrictions.
Unable to provide accurate variables.

Annotations

Annotations not available due to copyright restrictions

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!